Beyond Genomics - Targeting the Epigenome in Diffuse Large B-Cell Lymphoma

Approximately one third of patients with diffuse large B-cell lymphoma (DLBCL) relapse after first-line therapy. Outcome of relapsed/refractory DLBCL remains poor and there is an unmet need for novel agents to improve treatment of this patient population. Remarkable progress has recently been made in the development of "epigenetic drugs" and in our understanding of the epigenetic basis of DLBCL. Epigenetics define mechanisms of regulating cellular functions without changing the genetic code. Key elements of the epigenome are chromatin modifications in form of DNA methylation as well as post-translational modifications of histones.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vQtHLq
via IFTTT